Healthcare
Based on ARK ETF real-time + 13F quarterly filings
13F data may be delayed up to 90 days.
※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.
Iovance Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing and commercializing cell therapies for cancer. Their main products include Amtagvi and Proleukin, used to treat melanoma and other solid tumors. The company is a key player in the emerging field of autologous T cell immunotherapy.
AI-generated summary. Not investment advice.